Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: A multicentre, open-label, phase 2 trial

Gary K. Schwartz*, William D. Tap, Li Xuan Qin, Michael B. Livingston, Samir D. Undevia, Bartosz Chmielowski, Mark Agulnik, Scott M. Schuetze, Damon R. Reed, Scott H. Okuno, Joseph A. Ludwig, Vicki Keedy, Petra Rietschel, Andrew S. Kraft, Douglas Adkins, Brian A. Van Tine, Bruce Brockstein, Vincent Yim, Christiana Bitas, Abdul AbdullahCristina R. Antonescu, Mercedes Condy, Mark A. Dickson, Shyamprasad Deraje Vasudeva, Alan L. Ho, L. Austin Doyle, Helen X. Chen, Robert G. Maki

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

139 Scopus citations

Fingerprint Dive into the research topics of 'Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: A multicentre, open-label, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences